静脉注射阿昔洛韦治疗生殖器疱疹。中期报告。

Intravenous acyclovir in genital herpes. An interim report.

作者信息

Mindel A, Adler M W, Sutherland S, Fiddian A P

出版信息

Am J Med. 1982 Jul 20;73(1A):347-50. doi: 10.1016/0002-9343(82)90121-8.

Abstract

Twenty-five patients with primary genital herpes were treated in a double-blind placebo-controlled randomized trial of intravenous acyclovir. Thirteen patients received the drug and 12 a placebo. Three in each group were male. In the acyclovir group 10 patients had true primary herpes compared with six in the control group. The median time to healing of all lesions was significantly decreased from 11 to seven days (p less than 0.05), and the median duration of viral shedding from all lesions was decreased from eight to two days (p less than 0.001). The time to cessation of new lesions was decreased from a median of two days to zero days (p less than 0.001). Intravenous acyclovir is an effective treatment in decreasing the length and severity of primary genital herpes.

摘要

25例原发性生殖器疱疹患者参与了一项关于静脉注射阿昔洛韦的双盲安慰剂对照随机试验。13例患者接受药物治疗，12例接受安慰剂治疗。每组各有3例男性。阿昔洛韦组有10例为真正的原发性疱疹，而对照组为6例。所有皮损愈合的中位时间从11天显著缩短至7天（p<0.05），所有皮损病毒排出的中位持续时间从8天降至2天（p<0.001）。新皮损停止出现的时间从中位2天降至0天（p<0.001）。静脉注射阿昔洛韦是一种有效治疗方法，可缩短原发性生殖器疱疹的病程并减轻其严重程度。